Treatment of relapsed adult acute myeloid leukemia;Traitement des leucémies aiguës myéloïdes de l'adulte en rechute

Bulletin du Cancer

Volumn 89, Issue 9, 2002, Pages 795-807

  Thomas, Xavier ^a   Le, Quoc Hung ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Acute myeloid leukemia; Acute promyelocytic leukemia; Allogeneic transplantation; Autologous transplantation; Chemotherapy regimens; Prognosis; Relapse

Indexed keywords

AMSACRINE; ANGIOGENESIS INHIBITOR; ARSENIC TRIOXIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; IDARUBICIN; MITOXANTRONE; MONOCLONAL ANTIBODY; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; TOPOTECAN; ZORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; DRUG INDUCED DISEASE; HUMAN; KIDNEY FAILURE; LEUKEMIA REMISSION; PARESTHESIA; POLYDIPSIA; PROMYELOCYTIC LEUKEMIA; REVIEW; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; LEUKEMIA, PROMYELOCYTIC, ACUTE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION;

EID: 0036748199     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-62.
2. Rowe JM. What is the best induction regimen for acute myelogenous leukemia? Leukemia 1998; 12: S16-9.
3. Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wörmann B, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999; 17: 3569-76.
4. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896-903.
5. Burnett A, Goldstone AH, Stevens RM, Harm IM, Rees JK, Gray RG, et al. Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MCR AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700-8.
6. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Mallatie Ematologiche Maligne del'Adulto (Gimema) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217-23.
7. Appelbaum FR, Clift RA, Buckner CD, Stewart P, Storb R, Sullivan KM, et al. Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first complete relapse. Blood 1983; 61: 949-53.
8. Tomas F, Gomez-Garcia de Soria V, Lopez-Lorenzo JL, Arranz R, Figuera A, Camara R, et al. Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission: importance of duration of first complete remission in final outcome. Bone Marrow Transplant 1996; 17: 979-84.
9. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 1988; 6: 232-8.
10. Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wörmann B, et al. Significance of cytogenetic abnormalities in a multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia. Blood 1998; 92(suppl.1): 78a-79a.
11. Peterson BA, Bloomfield CD. Re-induction of complete remissions in adults with acute non-lymphocytic leukemia. Leuk Res 1981; 5: 81-8.
12. Letendre L, Kiely JM, Hoagland HC. Reinduction chemotherapy for acute nonlymphocytic leukemia. Mayo Clin Proc 1984; 59: 618-21.
13. Rees JK, Gray RG, Swirsky D, Hayhoe FG. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 2: 1236-41.
14. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7: 1071-80.
15. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Büchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990; 4: 184-8.
16. Angelov L, Brandwein JM, Baker MA, Scott JG, Sutton DM, Keating A. Results of therapy for acute myeloid leukemia in first relapse. Leuk Lymphoma 1991; 6: 15-24.
17. Davis CL, Rohatiner AZ, Lim Z, Whelan JS, Oza AM, Amess J, et al. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br J Haematol 1993; 83: 404-11.
18. McCallum PK, Davis CL, Rohatiner AZ, Lim J, Gupta RK, Whelan JS, et al. Mitoxantrone and cytosine arabinoside as treatment for myelogenous leukemia (AML) at first recurrence. Leukemia 1993; 7: 1496-9.
19. Rassam SM, Turker A, Powles RL, Smith AG, Newland AC, Erskine JG, et al. Idarubicin for remission induction of acute myeloid leukemia: United Kingdom multicenter experience. Semin Oncol 1993; 20: 13-9.
20. Thalhammer F, Geissler K, Jager U, Kyrle PA, Pabinger I, Mitterbauer M, et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol 1996; 72: 216-22.
21. Welborn JL, Kopecky KJ, Meyers FJ, Vekh R, Shurafa M, Doroshow JH, et al. Carboplatin infusion in relapsed and refractory acute myeloid leukemia: a Southwest Oncology Group trial. Leukemia 1995; 9: 1126-9.
22. Harousseau JL, Hurteloup P, Reiffers J, Rigal-Huguet F, Hayat M, Dufour P, et al. Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia. Cancer Treat Rep 1987; 71: 991-2.
23. Brito-Babapulle F, Catovsky D, Newland AC, Goldman JM, Galton DA. Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone. Semin Oncol 1987; 14: 51-2.
24. Peters WG, Willemze R, Colly LP. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia. Eur J Haematol 1988; 40: 198-204.
25. Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, et al. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia: an active and well-tolerated regimen. J Clin Oncol 1988; 6: 213-7.
26. Harousseau JL, Reiffers J, Hurteloup P, Milpied N, Guy H, Rigal-Huguet F, et al. Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. J Clin Oncol 1989; 7: 45-9.
27. Jehn U, Heinemann V. Intermediate-dose AraC/m-AMSA for remission induction and high-dose AraC/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia. Hamatol Blutrransfus 1990; 33: 333-8.
28. Harousseau JL, Milpied N, Briere J, Desablens B, Ghandour C. Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia. Nouv Rev Fr Hematol 1990; 32: 227-30.
29. Pavlovsky S, Fernandez I, Palau V, Santarelli MT, De Bellis R, Ruiz-Arguelles G, et al. Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia. Ann Oncol 1991; 2: 441-2.
30. Carella AM, Carlier P, Pungolino E, Resegotti L, Liso V, Stasi R, et al. Idarubicin in combination with intermediaire-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The Gimema Cooperative Group. Leukemia 1993; 7: 196-9.
31. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993; 9: 343-50.
32. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995; 13: 11-8.
33. Vignetti M, Orsini E, Petri MC, Moleti ML, Andrizzi C, Pinto RM, et al. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience. Ann Oncol 1996; 7: 933-8.
34. Kornblau SM, Kantarjian H, O'Brien S, Andreeff M, Koller CA, Beran M, et al. CECA - cyclophosphamide, etoposide, carboplatin and cytosine arabinoside: a new salvage regimen for relapsed or refractory acute myelogenous leukemia. Leuk Lymphoma 1998; 28: 371-5.
35. Ferrara F, Melillo L, Montillo M, Leoni F, Pinto A, Mele G, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation. Ann Hematol 1999; 78: 380-4.
36. Martiat P, Ghilain JM, Ferrant A, Doyen C, Delannoy A, Chatelain C, et al. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomised study. Eur J Haematol 1990; 45: 164-7.
37. Vogler WR, McCarley DL, Stagg M, Bartolucci AA, Moore J, Martelo O, et al. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia: a Southeastern Cancer Study Group trial. Leukemia 1994; 8: 1847-53.
38. Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 1994; 83: 2086-92.
39. Kern W, Aul C, Maschmeyer G, Schonrock-Nabulsi R, Ludwig WD, Bartholomaus A, et al. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomised comparison. Leukemia 1998; 12: 1049-55.
40. Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 trial). Leukemia 1999; 13: 1214-20.
41. Karanes C, Kopecky KJ, Head DR, Grever MR, Hynes HE, Kraut EH, et al. A phase III comparison of high dose ARA-C (Hidac) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia. Southwest Oncology Group study. Leuk Res 1999; 23: 787-4.
42. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212-20.
43. Sanz MA, Sanz GF, Martinez JA, Senent L, Lopez F, Palau J, et al. Carboplatin alone or in combination in high-risk acute nonlymphoblastic leukemia. Ann Oncol 1992; 3 (suppl-3): S39-42.
44. Cortes J, Estey E, Beran M, O'Brien S, Giles F, Koller C, et al. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymphoma 2000; 36: 479-84.
45. Estey EH, Thall P, Wang X. Routine use of fludarabine- or topotecan-containing chemotherapy is not indicated in AML, RAEB-T, or RAEB. Blood 2000; 96 (suppl. 1): 504a.
46. Giles FJ, Garcia-Manero G, Cortes JE, Baker SD, Miller CB, O'Brien SM, et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 2002; 20: 656-64.
47. Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, et al. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol 1999; 457: 47-56.
48. Gorin NC, Labopin M, Fouillard L, Meloni G, Frassoni F, Iriondo A, et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. Bone Marrow Transplant 1996; 18: 111-7.
49. Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80: 1090-3.
50. Clift RA, Buckner CD, Appelbaum FR, Schoch G, Petersen FB, Bensinger WI, et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992; 10: 1723-9.
51. Brown RA, Wolff SN, Fay JW, Pineiro L, Collins RH, Lynch JP, et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukaemia in untreated first relapse: a study by the North American Marrow Transplant Group. Blood 1995; 85: 1391-5.
52. Sierra J, Storer B, Hansen JA, Bjerke JW, Martin PJ, Petersdorf EW, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1997; 89: 4226-35.
53. Michallet M, Thomas X, Vernant JP, Kuentz M, Socié G, Espérou-Bourdeau H, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société française de greffe de moelle (SFGM). Bone Marrow Transplant 2000; 26: 1157-63.
54. Gale RP, Horowitz MM, Rees JK, Gray RG, Oken MM, Estey EH, et al. Chemotherapy versus transplant for acute myelogenous leukemia in second remission. Leukemia 1996; 10: 13-9.
55. Reiffers J. HLA-identical sibling hematopoietic stem cell transplantation for acute myeloid leukemia. In: Atkinson K, ed. Clinical bone marrow and blood stem cell transplantation. Cambridge: Cambridge University Press, 2000; 433-45.
56. Ringden O, Labopin M, Gluckman E, Hows JM, Bradley BA, Kolb HJ, et al. Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Bone Marrow Transplant 1997; 19: 963-8.
57. Sierra J, Storer B, Hansen JA, Martin PJ, Petersdorf EW, Woolfrey A, et al. Unrelated donor marrow transplantation for acute myeloid leukaemia: an update of the Seattle experience. Bone Marrow Transplant 2000; 26: 397-404.
58. Craddock C. Non-myeloablative stem cell transplants. Curr Opin Hematol 1999; 6: 383-7.
59. Storb R. Nonmyeloablative preparative regimens: how relevant for acute myelogenous leukemia? Leukemia 2001; 15: 662-3.
60. Michallet M, Bilger K, Garban F, Attal M, Huyn A, Blaise D, et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: Impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 2001; 19: 3340-9.
61. McSweeney PA, Niederwieser D, Shizuru JA, Sandmeier BM, Molina AJ, Maloney DJ, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies replacing high-dose cytotoxic therapy with graft versus tumor effects. Blood 2001; 97: 3390-400.
62. Hervé P, Rozenbaum A, Plouvier E, Flesch M, Cahn JY, Farradji A, et al. Autologous bone marrow transplantation in acute myeloid leukemia in relapse or in complete remission. Cancer Treat Rep 1982; 66: 1983-5.
63. Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986; 315: 141-7.
64. Santos GW, Saral R, Burns WH, Braine HG, Sensenbrenner LL, Wingard JR, et al. Allogeneic syngeneic and autologous marrow transplantation in the acute leukemias and lymphomas: Baltimore experiences. Acta Haematol 1987; 78: 175-80.
65. Körbling M, Hunstein W, Fliedner TM, Cayeux S, Dorken B, Fehrentz D, et al. Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. Blood 1989; 74: 1898-904.
66. Meloni G, De Fabritiis P, Petti MC, Mandelli F. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 1990; 75: 2282-5.
67. Dusenbery KE, Daniels KA, McClure JS, McGlave PB, Ramsay NK, Blazar BR, et al. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys 1995; 31: 119-28.
68. Mehta J, Powles R, Singhal S, Horton C, Tait D, Treleaven J. Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission. Bone Marrow Transplant 1996; 18: 119-23.
69. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75: 1606-14.
70. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, et al. Efficacy and safety of Mylotarg (gemtuzumab ozogamicin, CMA-676) in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-54.
71. Hall PD, Virella G, Willoughby T, Atchley DH, Kreitman RJ, Frankel AE. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukaemia. Clin Immunol 2001; 100: 191-7.
72. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, et al. Clinical and biological activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. Blood 2001; 97: 3361-9.
73. Steins MB, Padro T, Bieker R, Ruiz S, Kropff M, Kienast J, et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002; 99: 834-9.
74. Willemze R, Archimbaud E, Muus P. Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia: the EORTC Leukemia Cooperative Group. Leukemia 1993; 7 (suppl. I): 49-50.
75. Warrell RP, de Thé H, Wang ZY, Degos L. Acute promyelocyric leukemia. N Engl J Med 1993; 329: 177-89.
76. Mann KK, Shao W, Miller WH. The biology of acute promyelocytic leukemia. Curr Oncol Rep 2001; 3: 209-16.
77. Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol 1998; 16: 78-85.
78. Chou WC, Tang JL, Yao M, Liang YJ, Lee FY, Lin MT, et al. Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: a high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment. Leukemia 1997; 11: 921-8.
79. Fenaux P, Chomienne C, Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13-25.
80. Sanz MA, Lo CF, Martin G, Avvisati G, Rayon C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the Pethema and Gimema cooperative groups. Blood 2000; 96: 1247-53.
81. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. Blood 1999; 94: 3015-21.
82. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH, on behalf of the MRC Adult Leukaemia Working Party. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131-43.
83. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72.
84. Degos L, Chomienne C, Daniel MT, Berger R, Dombret H, Fenaux P, et al. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid. Lancet 1990; 336: 1440-1.
85. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-9.
86. Chen ZX, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-9.
87. Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385-93.
88. Cortes JE, Kantarjian H, O'Brien S, Robertson LE, Koller C, HirshGinsberg C, et al. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994; 73: 2946-52.
89. Thomas X, Anglaret B, Thiebaut A, Belhabri A, Treille-Ritouet D, Fiere D, et al. Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy. Ann Hematol 1997; 75: 195-200.
90. Castagnola C, Lunghi M, Corso A, Tajana M, Zappasodi P, Dabusti M, et al. Management of acute promyelocytic leukemia relapse in the ATRA era. Haematologica 1998; 83: 714-7.
91. Warrell RP, Maslak P, Eardley A, Heller G, Miller WH, Frankel SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994; 8: 929-33.
92. Frankel SR, Eardley A, Heller G, Berman E, Miller WH, Dmitrovsky E, et al. All-trans retinoic acid for acute promyelocytic leukemia: results of the New York study. Ann Intern Med 1994; 120: 278-86.
93. Ohno R, Ohnishi K, Takeshita A, Tanimoto M, Murakami H, Kanamaru A, et al. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. Leukemia 1994; 8(suppl.3): S64-S69.
94. Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by alltrans retinoic acid. Blood 1997; 90: 967-73.
95. Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 2000; 14: 1371-7.
96. Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. Leukemia 2000; 14: 1006-13.
97. Muindi J, Frankel SR, Miller WH, Jakubowski A, Scheinberg DA, Young CW, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid 'resistance' in patients with acute promyelocytic leukemia. Blood 1992; 79: 299-303.
98. Delva L, Cornic M, Balitrand N, Guidez F, Micléa JM, Delmer A, et al. Resistance to all-trans retinoic acid (Atra) therapy in relapsing acute promyelocytic leukemia: study of in vitro Atra sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993; 82: 2175-81.
99. Kizaki M, Ueno H, Yamazoe Y, Shimada M, Takayama N, Muto A, et al. Mechanisms of retinoid resistance in leukemic cells: possible role of cytochrome P450 and P-glycoprotein. Blood 1996; 87: 725-33.
100. Shao W, Benedetti L, Lamph WW, Nervi C, Miller WH. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation. Blood 1997; 89: 4282-9.
101. Douer D, Estey E, Santillana S, Bennett JM, Lopez-Bernstein G, Boehm K, et al. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-trans retinoic acid. Blood 2001; 97: 73-80.
102. Takeuchi M, Yano T, Omoto E, Takahashi K, Kibata M, Shudo K, et al. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: clinical experience with a new synthetic retinoid, Am80. Leuk Lymphoma 1998; 31: 441-51.
103. Warrell RP, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90: 1621-5.
104. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 1998; 90: 124-33.
105. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-53.
106. Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia 2000; 14: 262-70.
107. Sun HD, Ma L, Hu XC, Zhang TD. Treatment of acute promyelocytic leukemia by Al-1 therapy. Chin J Integrat Chin Western Med 1992; 12: 170-2.
108. Huang SL, Guo Al, Xiang Y. Clinical study on the treatment of acute promyelocytic leukemia mainly with composite indigo naturalis tablets. Chin J Hematol 1995; 16: 26-8.
109. Zhang P, Wang SY, Hu LH. Arsenic trioxide-treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996; 17: 58-60.
110. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-8.
111. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed APL patients. Blood 1999; 94: 3315-24.
112. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-60.
113. 3). Mod Pathol 2000; 13: 954-61.
114. Soignet SL, Frankel S, Tallman M, Douer D, Scheinberg DA, Dahlberg S, et al. Arsenic trioxide (ATO) in relapsed acute promyelocytic leukemia (APL): the combined results and follow-up from the US pilot and multicenter trials. Blood 2000; 96: 827a.
115. Barbey JT, Soignet SL. Arsenic trioxide (ATO): analysis of QT prolongation on electrocardiogram (ECG). Blood 2000; 96: 318a.
116. Unnikrishnan D, Dutcher JP, Varshneya N, Lucariello R, Api M, Garl S, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 2001; 97: 1514-6.
117. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98: 266-71.
118. Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Arsenic trioxide-and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol 2001; 66: 274-9.
119. 3) ± all-trans retinoic acid (Atra): the French As98 study. Blood 2000; 96: 3578a.
120. Wang ZG, Rivi R, Delva L, Ksnig A, Scheinberg DA, Gambacorri-Passerini C, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood 1998; 92: 1497-504.
121. Jurcic JG, Caron PC, Miller WH Jr, Yao TJ, Maslak P, Finn RD, et al. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans rerinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 1995; 9: 244-8.
122. Mandelli F, Labopin M, Granena A, Iriondo A, Prentice G, Bacigalupo A, et al. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3). Bone Marrow Transplant 1994; 14: 293-8.
123. Sanz MA, Arcese W, de la Rubia J, Lo Coco F, Labopin M, Bacigalupo A, et al. Stem cell transplantation (SCT) for acute promyelocytic leukemia (APL) in the Atra era: a survey of the European Blood and Marrow Transplantation Group (EBMT). Blood 2000; 96: 522a.
124. Meloni G, Diverio D, Vignetti M, Avvisati G, Capria S, Petti MC, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of rhe PML/RARα fusion gene. Blood 1997; 90: 1321-5.
125. Roman J, Martin C, Torres A, Jimenez MA, Andres P, Flores R, et al. Absence of detectable PML-RARα fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia. Bone Marrow Transplant 1997; 19: 679-83.